First Tracks (TRAXV)

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

的First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued（TRAXV）股票的价格今天是$0.00，自市场开启。该公司市值为，日交易量为股。前一交易日收盘价为 。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买First Tracks股票的指南。